Tech Company Financing Transactions

Ceptaris Therapeutics Funding Round

Ceptaris Therapeutics closed a $4 million Series B investment round on 11/13/2006. Investors included Osage Partners, BioAdvance Ventures and TDH Capital Corporation.

Transaction Overview

Announced On
11/13/2006
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series B
Investors

Osage Partners (Lead Investor) (David Drahms)

BioAdvance Ventures (Barbara Schilberg)

TDH Capital Corporation

Proceeds Purpose
The Series B financing will support the continued development of Yaupon's multiple clinical programs targeting diverse medical needs in the treatment of lymphoma, addiction and neuropathic pain.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 400
Malvern, PA 19355
USA
Email Address
Overview
Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Profile
Ceptaris Therapeutics LinkedIn Company Profile
Social Media
Ceptaris Therapeutics Company Twitter Account
Company News
Ceptaris Therapeutics News
Facebook
Ceptaris Therapeutics on Facebook
YouTube
Ceptaris Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Steve Tullman
  Steve Tullman LinkedIn Profile  Steve Tullman Twitter Account  Steve Tullman News  Steve Tullman on Facebook
Chief Medical Officer
Jeffrey Wilkins
  Jeffrey Wilkins LinkedIn Profile  Jeffrey Wilkins Twitter Account  Jeffrey Wilkins News  Jeffrey Wilkins on Facebook
Chief Operating Officer
Douglas Gssl
  Douglas Gssl LinkedIn Profile  Douglas Gssl Twitter Account  Douglas Gssl News  Douglas Gssl on Facebook
VP - Bus. Development
Evan Dick
  Evan Dick LinkedIn Profile  Evan Dick Twitter Account  Evan Dick News  Evan Dick on Facebook
VP - General Counsel
Kamil Ali-Jackson
  Kamil Ali-Jackson LinkedIn Profile  Kamil Ali-Jackson Twitter Account  Kamil Ali-Jackson News  Kamil Ali-Jackson on Facebook
VP - Operations
Jeffrey Shaver
  Jeffrey Shaver LinkedIn Profile  Jeffrey Shaver Twitter Account  Jeffrey Shaver News  Jeffrey Shaver on Facebook
VP - R & D
Timothy Henkel
  Timothy Henkel LinkedIn Profile  Timothy Henkel Twitter Account  Timothy Henkel News  Timothy Henkel on Facebook


 

 

Browse more venture capital transactions:

Prev: 11/13/2006: Cerenis Therapeutics venture capital transaction
Next: 11/13/2006: Mascoma venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary